DHI
36
3
AON
25
4
TSCO
42
4
GS
65
16
ADI
54
4
KEY
24
2
HIG
48
5
URBN
67
3
HAS
29
3
NRG
32
5
ES
12
3
EQR
33
6
FE
34
4
HCA
37
7
UAL
73
3
O
26
16
CNX
67
4
AIZ
61
5
NSC
33
6
NDAQ
46
2
DHI
36
3
AON
25
4
TSCO
42
4
GS
65
16
ADI
54
4
KEY
24
2
HIG
48
5
URBN
67
3
HAS
29
3
NRG
32
5
ES
12
3
EQR
33
6
FE
34
4
HCA
37
7
UAL
73
3
O
26
16
CNX
67
4
AIZ
61
5
NSC
33
6
NDAQ
46
2
Financhill
Back

Adaptimmune Therapeutics PLC 10K Form

Sell
20

ADAP
Adaptimmune Therapeutics PLC

Last Price:
$0.60
Seasonality Move:
36.97%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q ADAP/Adaptimmune Therapeutics PLC Quarterly
2023-08-09 10Q ADAP/Adaptimmune Therapeutics PLC Quarterly
2023-05-12 10Q ADAP/Adaptimmune Therapeutics PLC Quarterly
2022-11-08 10Q ADAP/Adaptimmune Therapeutics PLC Quarterly
2022-08-04 10Q ADAP/Adaptimmune Therapeutics PLC Quarterly
2022-05-09 10Q ADAP/Adaptimmune Therapeutics PLC Quarterly

Receive ADAP News And Ratings

See the #1 stock for the next 7 days that we like better than ADAP

ADAP Financial Statistics

Sales & Book Value

Annual Sales: $60.3M
Cash Flow: $-54.9M
Price / Cash Flow: 0
Annual Sales: $0.31
Price / Book: 1.93

Profitability

EPS (TTM): -0.18000
Net Income (TTM): $-44.5M
Gross Margin: $192.7M
Return on Equity: -67.8%
Return on Assets: -15.08%

Adaptimmune Therapeutics PLC Earnings Forecast

Key Adaptimmune Therapeutics PLC Financial Ratios

  • The Gross Profit Margin over the past 7 years for ADAP is 709.74%.
  • The Selling, General & Administrative Expenses for ADAP have been equal to 119.13% of Gross Profit Margin.
  • The Research & Development expenses have been 209.87% of Revenue.
  • The Interest Expense is -1.52% of Operating Income.
  • The Net Earning history of ADAP is -188.90% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 3 years.

Adaptimmune Therapeutics PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ADAP
CUSIP: 00653A
Website: adaptimmune.com

Debt

Debt-to-Equity Ratio: 0.62
Current Ratio: 3.85
Quick Ratio: 3.54

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ADAP Technical Analysis vs Fundamental Analysis

Sell
20
Adaptimmune Therapeutics PLC (ADAP) is a Sell

Is Adaptimmune Therapeutics PLC a Buy or a Sell?